Esmolol in acute ischemic syndromes

Background β-Blockers have been shown to reduce both morbidity and mortality rates in patients with acute coronary syndromes. However, because of potential side effects, their use is limited in patients who might benefit the most from such therapy. It was thought that the use of an ultrashort-acting intravenous 13-blocker might produce similar results with fewer complications in those patients with relative contraindications to β-blocker therapy. Methods Accordingly, we evaluated the use of esmolol in patients with acute coronary syndromes and relative contraindication to β-blocker therapy in a prospective randomized trial. One hundred eight patients at 21 sites received an infusion of intravenous esmold or standard therapy on admission and were followed for 6 weeks from the day of admission. The primary efficacy outcome was a composite event consisting of any of the following that occurred during the index hospitalization: death, myocardial (re)infarction, recurrent ischemia, or arrhythmia as well as silent myocardial ischemia assessed by ambulatory electrocardiographic monitoring. Safety end points including hypotension, bradyarrhythmias, new or worsening congestive heart failure, and bronchospasm were also recorded. Results Event rates for primary end points were similar in the 2 groups: death (2% in the standard care group vs 4% in the group receiving esmolol), myocardial (re)infarction (4% standard vs 7% esmolol), ischemia (12% vs 13%), arrhythmias (4% vs 2%), and silent ischemia (13% vs 15%). There was a higher incidence of transient hypotension in the group receiving esmolol (2% vs 16%), but all such events were noted to resolve after discontinuation of the esmdd infusion. There were no additional differences in safety end points: bradycardia (2% for those receiving standard care vs 9% receiving esmolol), new congestive heart failure (10% vs 16%), bronchospasm (0% vs 7%), and heart block (2% vs 2%). Conclusions The use of on ultra-short-acting β-blocker such as esmolol might offer an alternative to patients with contraindications to standard β-blocker therapy. Although this trial had limited power to detect safely and efficacy differences between the 2 therapies, it was observed that safety end points, which occurred during esmold administration, resolved readily when the infusions were decreased or discontinued. Additional testing is needed to substantiate these findings.